PT - JOURNAL ARTICLE AU - Cross-sectional and longitudinal multicentre cohort study AU - Bernal, Jose AU - Schreiber, Stefanie AU - Ostendorf, Anna AU - Pfister, Malte AU - Geisendörfer, Jonas AU - Nemali, Aditya AU - Maass, Anne AU - Yakupov, Renat AU - Peters, Oliver AU - Preis, Lukas AU - Schneider, Luisa AU - Herrera, Ana Lucia AU - Priller, Josef AU - Spruth, Eike Jakob AU - Altenstein, Slawek AU - Schneider, Anja AU - Fliessbach, Klaus AU - Wiltfang, Jens AU - Schott, Björn H. AU - Rostamzadeh, Ayda AU - Glanz, Wenzel AU - Buerger, Katharina AU - Janowitz, Daniel AU - Ewers, Michael AU - Perneczky, Robert AU - Rauchmann, Boris-Stephan AU - Teipel, Stefan AU - Kilimann, Ingo AU - Laske, Christoph AU - Munk, Matthias H. AU - Spottke, Annika AU - Roy, Nina AU - Dobisch, Laura AU - Dechent, Peter AU - Scheffler, Klaus AU - Hetzer, Stefan AU - Wolfsgruber, Steffen AU - Kleineidam, Luca AU - Schmid, Matthias AU - Berger, Moritz AU - Jessen, Frank AU - Wirth, Miranka AU - Düzel, Emrah AU - Ziegler, Gabriel TI - Arterial hypertension and Aβ-amyloid accumulation have spatially overlapping effects on posterior white matter hyperintensity presence and volume AID - 10.1101/2022.07.19.22277546 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.19.22277546 4099 - http://medrxiv.org/content/early/2022/07/19/2022.07.19.22277546.short 4100 - http://medrxiv.org/content/early/2022/07/19/2022.07.19.22277546.full AB - Importance Posterior white matter hyperintensities (WMH) in subjects across the Alzheimer’s disease (AD) spectrum with minimal vascular pathology suggests that amyloid pathology —not just arterial hypertension— impacts WMH, adversely influencing cognition.Objective To characterise the effects of AD pathology, namely β-amyloid (Aβ) and hypertension on WMH and cognition.Design Cross-sectional and longitudinalSetting MulticentreParticipants We analysed data from subjects with normal cognition (NC), subjective cognitive decline (SCD), and mild cognitive impairment (MCI) enrolled in the ongoing observational multicentre DZNE Longitudinal Cognitive Impairment and Dementia Study. We focused on participants with available magnetic resonance imaging (MRI), cerebrospinal fluid biomarkers, and cognitive and hypertension information. We conducted analyses between 02.2022 and 06.2022.Intervention(s) (for clinical trials) or Exposure(s) (for observational studies) NAMain Outcomes and Measures Spatial distribution and volume of MRI WMH in relation to Aß42/40 levels and arterial hypertension. Mediation of the relationship between Aβ positivity and hypertension on cognition by the regional WMH volume.Results We included 355 participants (median age 70.3 [IQR 66.0-74.4] years; 168 female; 121 NC, 154 SCD, 80 MCI). Hypertension and Aβ positivity were positively associated (pFTR<0.05) with WMH volume, with large spatial overlap in the occipital lobes (regression coefficient ± standard error; hypertension: 0.49±0.14; Aβ: 0.41±0.15), parietal lobes (hypertension: 0.62±0.23; Aβ: 0.61±0.24), corona radiata (hypertension: 0.55±0.19; Aβ: 0.61±0.24), optic radiation (hypertension: 0.64±0.19; Aβ: 0.50±0.20) and splenium (hypertension: 0.38±0.13; Aβ: 0.39±0.13). Global and occipital WMH volumes were strongly associated cognitive changes over a three-year period, estimated with preclinical Alzheimer’s cognitive composite 5 (PACC5) (global: 2.18±0.61, pFDR<0.01; occipital: 3.31±0.75, pFDR<0.01), regardless of Aβ and hypertension status. The association between Aβ positivity and baseline cognitive performance (direct-memory: -0.42±0.08, pFDR<0.01; executive: - 0.28±0.28, pFDR<0.01) was partially mediated by WMH in the corona radiata (indirect-memory: -0.04±0.02, pFDR<0.05; executive: -0.04±0.02, pFDR<0.01) and splenium (indirect-memory: -0.02±0.02, pFDR<0.01; executive: -0.04±0.02, pFDR<0.01). Evidence supporting hypertension affected cognition was insufficient (direct-memory: 0.03±0.07, pFDR=0.683; executive: -0.05±0.07, pFDR=0.499; PACC5 change: 0.01±0.02, pFDR =0.588).Conclusions and Relevance Posterior white matter is susceptible to vascular disease and Aβ accumulation. Its deterioration is involved in the association between Aβ and cognitive dysfunction. Posterior WMH could be a promising target to tackle the downstream damage related to the interacting and potentiating effect of these two pathologies.Trial Registration German Clinical Trials Register (DRKS00007966, 04/05/2015)Question Is the spatial distribution and volume of cerebral white matter hyperintensities (WMH) related to arterial hypertension, amyloid pathology, and cognition?Findings In this cross-sectional and longitudinal cohort study, WMH increased with hypertension and amyloid, with a spatial overlap in occipital and parietal lobes. Amyloid is involved in the relationship between WMH in corona radiata and splenium on cognitive performance. Global, occipital, and frontal WMH were strongly associated cognitive performance and worsening, regardless of hypertension and amyloid status.Meaning Posterior white matter is susceptible to vascular disease and amyloid pathology; its damage plays a role in the effect of amyloid pathology on cognition.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the German Center for Neurodegenerative Diseases (DZNE; reference number BN012) and funded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG; Project-ID 425899996).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the ethical committees of the medical faculties of all participating sites: the ethical committees of Berlin (Charite, University Medicine), Bonn, Cologne, Goettingen, Magdeburg, Munich (Ludwig-Maximilians-University), Rostock, and Tuebingen. The process was led and coordinated by the ethical committee of the medical faculty of the University of Bonn. All commitees gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript Aββ-amyloidADAlzheimer’s diseaseATNAmyloid/Tau/NeurodegenerationBregression coefficientCAACerebral amyloid angiopathyCATComputational Anatomy ToolboxCERADConsortium to Establish a Registry for Alzheimer’s DiseaseCNNon-complaining healthy controlsCSFCerebrospinal fluidCSVDCerebral small vessel diseaseFAFlip angleFDRFalse discovery rateFLAIRFluid Attenuated Inversion RecoveryGMGrey matterIQRInterquartile rangeMCIMild cognitive impairmentMRIMagnetic resonance imagingNCNormal cognitionPACC5Preclinical Alzheimer’s Cognitive Composite scoresROIRegion of interestROCReceiver operating characteristicSCDSubjective cognitive declineSDStandard deviationSEStandard errorSPMStatistical parametric mappingTEEcho timeTIInversion timeTICVTotal intracranial volume TR Repetition timeVBMVoxel-based morphometry WM White matterWMHWhite matter hyperintensities